44th ISICEM

P212

Katia Donadello

Angiotensin II in the management of refractory septic shock

P213

Chema Strik-Lips

Angiotensin 2 in septic shock, non-responders fail to raas?

P214

Paulina Aldakauskaite

Early giapreza (angiotensin ii) impact on microcirculation in decompensated septic distributive shock ? pilot study

P215

Natalija Planinc Strunja?

The impact of angiotensin ii on hemodynamic stabilization in refractory septic shock: a single-center experience

P216

Brian Woolley

Variation in reinforcement learning-guided treatment by clinical sepsis subtype

P218

Teresa Klaus

The international, prospective COSMOS (CytoSorb treatment of critically ill patients) registry: interim results from the first 230 patients

P219

Rita Captivo

Hemoadsorption with CytoSorb® in patients with septic shock

P225

Emoke Henrietta Kovács

Thrombomodulin in sepsis-associated coagulopathy: a systematic review and meta-analysis

P234

Nirmala Manjappachar

Comparison of immunomodulation strategies and associated outcomes in critically ill COVID-19 patients: a multicenter cohort study

P249

Evangelos Giamarellos?Bourboulis

Emapalumab treatment for anticipated clinical benefit in sepsis driven by the interferon-gamma endotype (the EMBRACE trial)